07:28 AM EST, 12/09/2024 (MT Newswires) -- Merck ( MRK ) said Monday that its phase 3 study evaluating Keytruda combined with chemotherapy and followed by maintenance with Lynparza, with or without bevacizumab, in patients with non-mutated advanced epithelial ovarian cancer met its primary endpoint of progression-free survival benefit.

Keytruda plus Lynparza regimen showed "a statistically significant and clinically meaningful" improvement in progression-free survival for these patients compared with chemotherapy alone, Merck ( MRK ) said.

The trial, however, did not meet its secondary endpoint of overall survival, the company said, adding that Keytruda's role in the intention-to-treat population "remains uncertain at this time."

Safety profiles of Keytruda and Lynparza aligned with prior findings for each therapy, Merck ( MRK ) said.